Reducing consent form length: Stakeholder support, evidence-based strategies, and regulatory requirements

IRB Ethics and Human Research

Volumn 39, Issue 2, 2017, Pages 18-20

  Corneli, Amy ^a   Sugarman, Jeremy ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85021741894     PISSN: 01937758     EISSN: 23262222     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. U.S. Government. Federal Policy for the Protection of Human Subjects. Final rule. Federal Register 2017; 82(12):7149-7274.
2. U.S. Government 2017, §.116(a)(5)(i).
3. Menikoff J, Kaneshiro J, Pritchard I. The Common Rule, updated. NEJM. January 19, 2017 [epub ahead of print].
4. Corneli A et al. Evidence-based strategies for shortening informed consent forms in clinical research. Journal of Empirical Research on Human Research Ethics January 2017 [epub ahead of print].
5. Kass NE et al. Length and complexity of US and international HIV consent forms from federal HIV network trials. Journal of General Internal Medicine 2011;26(11):1324-1328
6. Matsui K et al. A randomized controlled trial of short and standard-length consent forms for a genetic cohort study: Is longer better? Journal of Epidemiology 2012;22(4):308-316.
7. Dresden GM, Levitt MA. Modifying a standard industry clinical trial consent form improves patient information retention as part of the informed consent process. Academic Emergency Medicine 2001;8(3):246-252;
8. Stunkel L et al. Comprehension and informed consent: Assessing the effect of a short consent form. IRB: Ethics & Human Research 2010;32(4):1-9;
9. Enama ME et al. Randomization to standard and concise informed consent forms: Development of evidence-based consent practices. Contemporary Clinical Trials 2012;33(5):895-902;
10. HPTN: HIV Prevention Trials Network. HPTN 073: Pre-Exposure Prophylaxis (PrEP) initiation and adherence among black men who have sex with men (BMSM) in three U.S. cities. https://www.hptn.org/research/studies/136.
11. HPTN: HIV Prevention Trials Network. HPTN 069: A phase II randomized, double-blind, study of the safety and tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for Pre-Exposure Prophylaxis (PrEP) to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. https://www.hptn.org/research/stud-ies/110
12. Poll Everywhere Inc. Poll Everywhere Mobile Audience Response System. www.pol-leverywhere.com.
13. U.S. Government. NPRM for Revisions to the Common Rule. Federal Register 2015;80(173):53993-54060.